"Potential Therapy Discovered For Deadly Breast Cancer That Has Few Treatment Options"
Researchers at the Icahn School of Medicine at Mount Sinai have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December. Research teams led by Jian Jin, PhD, director of the Mount Sinai Center for Therapeutics Discovery, and Ramon Parsons, MD, PhD, director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, developed MS1943 as a first-in-class small-molecule agent that selectively degrades EZH2. "Our findings suggest that EZH2 selective degraders such as MS1943 may provide an emerging therapeutic approach for the treatment of triple-negative breast cancer," said Dr. Jin.
— Jian Jin, PhD, Professor, Oncological Sciences, Pharmacological Sciences, Mount Sinai Professor, Therapeutics Discovery, Director, Mount Sinai Center for Therapeutics Discovery, Co-Leader, Cancer Clinical Investigation, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
— Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute, Chair of Oncological Sciences, and Ward-Coleman Professor in Cancer Research of the Icahn School of Medicine at Mount Sinai